Biocept (BIOC) Stock | Nowhere To Go But Up Long Term

Biocept BIOC Stock NewsBiocept, Inc. (NASDAQ: BIOC)

Biocept is a stock that’s generating a ton of conversation lately. As with just about all stocks, there are the investors that love it, and the investors that hate it. However, I’m personally on the love side of the equation as I think that Biocept truly has the ability to change the way we go about cancer diagnostics; and since early detection is key to survival rates, BIOC may have the ability to reduce the cancer death toll in the US and around the world…The big question is, is that profitable? Well of course it is! Today, we’ll talk about how Biocept is changing the world of cancer diagnostics, how this change could become an incredibly profitable endeavor, and what we can expect to see from the stock moving forward. So, let’s get right to it…

How BIOC Is Changing The World Of Cancer Diagnostics

We all know that if you catch cancer in late stages, your chances of survival are much lower than if the cancer is caught in early stages. Knowing this, Biocept is working on a way to help with the early detection of cancer. The company has innovated the technology needed to determine if someone has or even may have cancer in the future through the use of a simple blood test! The proof of their ability to do so has been provided in two very recent announcements.
Subscribe to The Prudent Speculator

The first announcement revolved around a breast cancer diagnostics study. In the study, BIOC performed biopsies on several different blood samples taken from women with various stages of a specific type of breast cancer. When the blood sample biopsy results were compared to results of the more invasive, yet traditional tissue biopsy, the results proved to be a match; ultimately showing that cancer can be detected without an invasive tissue biopsy. Another announcement that recently came in was the fact that the company added a new test to its profile that’s designed to pinpoint those who are receptive to having lung cancer in the future.

If cancer can be detected through the use of a simple blood sample, the world of cancer diagnostics is changing in front of our eyes. The reality is that if this is indeed the case, adding a cancer tests to normal, annual blood testing can help with the early detection, and therefore, successful treatment of cancer. Ultimately, this non-invasive biopsy can greatly help with regard to increasing cancer survival rates.

Can This Be Profitable?

I think this technology can be incredibly profitable. Think about it, everyone knows how devastating cancer is, and everyone who has it wishes they caught it earlier. Unfortunately however, tissue biopsies are invasive and scary to many patients. Most people would simply prefer simple blood work. The only problem right now is that Biocept is currently only focused on a few specific types of cancer. However, as their portfolio of successful tests continues to grow, I think we’re in for massive long term gains!

What Do You Think?

Do you think liquid biopsies will prove to be profitable? Why or why not? Let us know in the comments below!

1 thought on “Biocept (BIOC) Stock | Nowhere To Go But Up Long Term”

  1. I do agree totally that this is an exciting time for the company as well as the industry. I’d like to know what the expected reimbursement is for each of their products and the recurring frequency of tests conducted. Because this company is expanding into tests of different types of cancer the future is truly exciting. EPS and revenue continuing to grow per each subsequent quarter is a great sign.


Leave a Comment